phrykt

MoonLake Immunotherapeutics (MLTX): who owns it and who trades it

As of Nov 16, 2026, MLTX insiders reported 26 open-market sales worth $81.1M and no purchases in the last 12 months, with 14% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mark N Lampert (Director), with $63M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling MoonLake Immunotherapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns MLTX

173 funds and institutions reported MLTX shares worth $1.5B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Bvf Inc with 21.7%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Bvf Inc21.7%
Deep Track Capital, LP9.5%
T. Rowe Price Investment Management, Inc.5.8%
D. E. Shaw & Co., Inc.4.6%
Cormorant Asset Management, LP4.4%
Jupiter Topco LLC4.2%
Logos Global Management LP3.6%
Weiss Asset Management LP3.5%
Citadel Advisors LLC2.7%
Two Sigma Investments, LP2.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Bvf Inc16.00M21.74%$312MNo change
Deep Track Capital, LP7.00M9.51%$136M+9%
T. Rowe Price Investment Management, Inc.4.28M5.81%$83.3M–
D. E. Shaw & Co., Inc.3.37M4.57%$65.5M+41%
Cormorant Asset Management, LP3.21M4.35%$62.4M-28%
Jupiter Topco LLC3.09M4.19%$60.1M–
Logos Global Management LP2.67M3.63%$52.1M+78%
Weiss Asset Management LP2.58M3.51%$50.3M+51%
Citadel Advisors LLC1.97M2.68%$38.4M+49%
Two Sigma Investments, LP1.72M2.33%$33.4M+53%
Mpm Bioimpact LLC1.61M2.18%$31.3M-11%
Vivo Capital, LLC1.40M1.90%$27.3M+40%
JPMorgan Chase & Co1.39M1.88%$27.6M–
Point72 Asset Management, L.P.1.16M1.57%$22.6M-15%
BlackRock, Inc.1.09M1.49%$21.3M+7%
T. Rowe Price Associates1.04M1.41%$20.3M-20%
Balyasny Asset Management L.P.912,7151.24%$17.8M-14%
Great Point Partners LLC855,8131.16%$16.7M+71%
Jane Street Group, LLC853,3861.16%$16.6M+88%
Candriam S.C.A.769,7661.05%$15M-6%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, MLTX insiders reported $0 of open-market purchases and $81.1M of sales. 14% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$81.1M
26 trades, 4 people
Sales under a 10b5-1 plan
14%
Share of sale value
Latest trade
Jul 27, 2026
Filed Jul 29, 2026

Purchases and sales by month

$63M$63MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jul 27, 2026Kristian ReichChief Scientific OfficerSale plan1,100$20.00$22KForm 4
Jul 22, 2026Kristian ReichChief Scientific OfficerSale plan2,448$20.00$49KForm 4
Jul 21, 2026Kristian ReichChief Scientific OfficerSale plan50,000$20.02$1MForm 4
Jul 20, 2026Kristian ReichChief Scientific OfficerSale plan43,700$20.09$878KForm 4
Jul 15, 2026Kristian ReichChief Scientific OfficerSale plan16,105$20.01$322KForm 4
Jul 10, 2026da Silva Jorge SantosCEOSale plan68,289$20.02$1.4MForm 4
Jul 9, 2026da Silva Jorge SantosCEOSale plan33,936$20.01$679KForm 4
Jul 1, 2026da Silva Jorge SantosCEOSale plan47,775$20.03$957KForm 4
Jun 22, 2026Matthias BodenstedtCFOSale plan39,120$22.04$862KForm 4
Jun 18, 2026Matthias BodenstedtCFOSale plan2,794$19.60$54.8KForm 4
Jun 17, 2026Matthias BodenstedtCFOSale plan15,082$19.68$297KForm 4
Jun 17, 2026Kristian ReichChief Scientific OfficerSale plan50,000$19.43$972KForm 4
Jun 16, 2026Kristian ReichChief Scientific OfficerSale plan50,000$18.70$935KForm 4
Jun 15, 2026Kristian ReichChief Scientific OfficerSale plan50,000$18.89$944KForm 4
May 11, 2026Matthias BodenstedtCFOSale plan13,653$20.02$273KForm 4
Apr 14, 2026Matthias BodenstedtCFOSale plan2,426$19.56$47.5KForm 4
Apr 13, 2026da Silva Jorge SantosCEOSale51,873$18.23$946KForm 4
Apr 10, 2026da Silva Jorge SantosCEOSale98,127$18.41$1.8MForm 4
Apr 10, 2026Matthias BodenstedtCFOSale plan1,925$19.51$37.6KForm 4
Apr 9, 2026Matthias BodenstedtCFOSale plan85,870$18.94$1.6MForm 4
Mar 31, 2026Mark N Lampert +9DirectorSale1.93M$16.79$32.4MForm 4
Mar 31, 2026Mark N Lampert +9DirectorSale1.57M$16.79$26.3MForm 4
Mar 31, 2026Mark N Lampert +9DirectorSale248,530$16.79$4.2MForm 4
Dec 9, 2025da Silva Jorge SantosCEOSale70,000$14.49$1MForm 4
Dec 9, 2025Kristian ReichChief Scientific OfficerSale72,908$14.43$1.1MForm 4
Dec 8, 2025da Silva Jorge SantosCEOSale130,000$15.08$2MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Mark N LampertDirector, 10% owner–$63MMar 31, 2026
da Silva Jorge SantosChief Executive Officer, Director–$8.7MJul 10, 2026
Kristian ReichChief Scientific Officer–$6.2MJul 27, 2026
Matthias BodenstedtChief Financial Officer–$3.2MJun 22, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

MLTX short interest

Moderate short interest. 6.4% of MLTX shares are sold short: about 1 share in 16. Over the last 12 reports the number of shares short barely changed.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 5.47M MLTX shares were sold short, 6.4% of the shares outstanding, down 30.1% from the report before. At the average daily volume of 1.92M shares, buying them all back would take about 2.9 trading days (days to cover).

Shares short, % of all shares

6.43%May 15Oct 3011.1%

Days to cover

2.9May 15Oct 307.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20265.47M6.43%-30%1.92M2.9
Oct 15, 20267.83M9.20%-3%1.92M4.1
Sep 30, 20268.05M9.46%-10%1.90M4.2
Sep 15, 20268.95M10.51%+25%1.47M6.1
Aug 31, 20267.14M8.39%+5%1.07M6.7
Aug 14, 20266.82M8.01%+19%1.62M4.2
Jul 31, 20265.72M7.77%-10%864,6936.6
Jul 15, 20266.33M8.60%-3%1.27M5.0
Jun 30, 20266.56M8.91%+23%1.86M3.5
Jun 15, 20265.32M7.23%-4%736,8147.2
May 29, 20265.57M7.56%+2%803,9776.9
May 15, 20265.47M7.43%-13%1.10M5.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

MoonLake Immunotherapeutics company events

MoonLake Immunotherapeutics filed 11 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Sep 30, 2026AnnouncementMoonLake Immunotherapeutics submitted a Biologics License Application to the U.S. Food and Drug Administration, seeking approval of its tri-specific nanobody sonelokimab for the treatment of moderate-to-severe hidradenitis suppurativa in adults and pediatric patients 12 years of age and older. Filing
  3. Aug 10, 2026ResultsReleased financial results. Filing
  4. Jul 15, 2026AnnouncementThe underwriters of the previously announced public offering of Class A ordinary shares, par value $0.0001 per share, of MoonLake Immunotherapeutics and, in lieu of Ordinary Shares to certain investors that so choose, pre-funded warrants to purchase Ordinary Shares, exercised in full their option… Filing
  5. Jun 25, 2026AgreementMoonLake Immunotherapeutics entered into an underwriting agreement with Leerink Partners LLC, as the representative of the underwriters named therein, to issue and sell, in a public offering, 9,000,000 Class A ordinary shares, par value $0.0001 per share, at a public offering price of $20.00 per… Filing
  6. Jun 22, 2026AnnouncementResults from the Phase 3 VELA clinical trials at Week 52 Week 52 data for SLK showed consistent and further improvement in all clinical scores, compared to Week 16 data. Filing
  7. Jun 9, 2026LeadershipDeparture of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
  8. Jun 1, 2026AgreementMoonLake Immunotherapeutics entered into a Master Commercial Supply Agreement with Vetter Pharma International GmbH. Filing
  9. May 11, 2026ResultsReleased financial results. Filing
  10. Feb 23, 2026LeadershipSimon Sturge notified the Board of Directors of the Company of his intent to resign as a member of the Board, effective as of February 28, 2026. Filing
  11. Jan 8, 2026AnnouncementMoonLake Immunotherapeutics issued a press release providing an update following the positive feedback received from the U.S. Food and Drug Administration regarding the clinical evidence strategy for Sonelokimab in Hidradenitis Suppurativa, based on the Type B meeting requested by the Company. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

MoonLake Immunotherapeutics financials

Famous investors that hold MLTX

5 of the 50 well-known investors we track reported holding MLTX in their latest 13F filing. The largest position is Jim Simons's, worth $20.1M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20261.72M$20.1M0.0%+167%
Ken Griffin · Citadel AdvisorsQ3 20261.71M$20M0.0%-14%
Israel Englander · Millennium ManagementQ3 20261.53M$18M0.0%+141%
Stanley Druckenmiller · Duquesne Family OfficeQ3 2026494,000$5.8M0.1%New
Paul Tudor Jones · Tudor Investment CorpQ3 202645,612$534K0.0%-22%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about MoonLake Immunotherapeutics (MLTX) stock

Who owns the most MLTX stock?

The largest reported owner of MoonLake Immunotherapeutics (MLTX) is Bvf Inc, with 21.7% of the company. In total, 173 funds and institutions reported holding MLTX at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are MLTX insiders buying or selling?

In the last 12 months, MLTX insiders reported no open-market purchases and 26 sales worth $81.1M. The latest trade was on Jul 27, 2026. See every trade.

What is the short interest in MLTX?

As of Oct 30, 2026, 5.47M MLTX shares were sold short, 6.4% of the shares outstanding, down 30.1% from the report before. At the average daily volume of 1.92M shares, buying them all back would take about 2.9 trading days (days to cover). See the history.

Which famous investors hold MLTX?

5 of the 50 well-known investors we track reported MLTX in their latest 13F filing, including Jim Simons, Ken Griffin, Israel Englander. The largest position is worth $20.1M. See all holders.

Executive pay

MoonLake Immunotherapeutics's chief executive was paid a total of $4.9M for the year ended Dec 31, 2025, up 252% from $1.4M the year before. In the last 12 months, MoonLake Immunotherapeutics's executives and directors bought no stock on the open market and sold $81.1M.

Chief executive, total pay$4.9MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$341KThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$4.7MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.